Mandate

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), an innovative and integrated pharmaceutical company focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment, listed on Nasdaq Stockholm, in connection with a directed share issue whereby the company raised proceeds of SEK 210 million before issue costs.

The share issue was directed to a number of selected Swedish and international institutional investors on the basis of an accelerated bookbuilding process.

Vinge’s team consisted of Dain Hård Nevonen, Amanda Knutsson and Lorin Arabi.

Related

Vinge advises Lagercrantz Group in connection with the acquisition of ORAX

Lagercrantz Group has acquired all shares in AB ORAX, a leading provider of products for management and maintenance in the funeral and cemetery sector.
June 04, 2025

Vinge has advised Eleda in connection with its acquisition of Rail Solutions Scandinavia AB, Gridtec AB, Quantity Surveying Konsult Stockholm AB, Voene AB, Vägservice centralen i Norden AB and Frästech AB.

Vinge has advised the leading infrastructure group Eleda in connection with its parallel acquisitions of Rail Solutions Scandinavia (railway maintenance), Gridtec (engineering consultancy in electric power), Quantity Surveying Konsult Stockholm (cost control and project management), Voene (traffic safety), Vägservice centralen i Norden and Frästech (road and bridge maintenance). The acquired businesses had a strong profitability with a combined turnover of approximately 200 MSEK in 2024.
June 04, 2025